Literature DB >> 2183870

Where next with therapy in advanced neuroblastoma?

C R Pinkerton1.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2183870      PMCID： PMC1971292          DOI： 10.1038/bjc.1990.77

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  21 in total

1.  High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.

Authors:  M E Gore; A H Calvert; L E Smith
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

2.  Carboplatin or cisplatin?

Authors:  C R Pinkerton; I J Lewis; A D Pearson; M C Stevens; J Barnes
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

3.  Screening for neuroblastoma.

Authors:  G J Draper
Journal:  BMJ       Date:  1988-07-16

4.  International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

Authors:  G M Brodeur; R C Seeger; A Barrett; F Berthold; R P Castleberry; G D'Angio; B De Bernardi; A E Evans; M Favrot; A I Freeman
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

5.  Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients.

Authors:  B H Kushner; L Helson
Journal:  J Clin Oncol       Date:  1987-11       Impact factor: 44.544

6.  Chemotherapy of advanced neuroblastoma: does adriamycin contribute?

Authors:  J Ninane; J Pritchard; J S Malpas
Journal:  Arch Dis Child       Date:  1981-07       Impact factor: 3.791

7.  Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group.

Authors:  S J Kellie; J De Kraker; J S Lilleyman; A Bowman; J Pritchard
Journal:  Eur J Cancer Clin Oncol       Date:  1988-05

8.  Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.

Authors:  J de Kraker; J Pritchard; O Hartmann; J Ninane
Journal:  Pediatr Hematol Oncol       Date:  1987       Impact factor: 1.969

Review 9.  Neuroblastoma--an overview of laboratory studies aimed at inducing tumor regression by initiation of differentiation or administration of antitumor drugs.

Authors:  B T Hill
Journal:  Pediatr Hematol Oncol       Date:  1986       Impact factor: 1.969

10.  Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.

Authors:  A D Ho; J Thaler; R Willemze; F Lauria; G Derossi; R Kuse; P Stryckmans; C M Blanc; F Cataldo; G McVie
Journal:  Bone Marrow Transplant       Date:  1989-01       Impact factor: 5.483
View more
  3 in total

1.  The radiation dose-rate effect in two human neuroblastoma cell lines.

Authors:  A Holmes; T J McMillan; J H Peacock; G G Steel
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

2.  Trends in survival for childhood cancer in Britain diagnosed 1971-85.

Authors:  C A Stiller; K J Bunch
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

3.  The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation.

Authors:  Annekathrin Heinze; Beatrice Grebe; Melanie Bremm; Sabine Huenecke; Tasleem Ah Munir; Lea Graafen; Jochen T Frueh; Michael Merker; Eva Rettinger; Jan Soerensen; Thomas Klingebiel; Peter Bader; Evelyn Ullrich; Claudia Cappel
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.